Business Information
The group's principal activity is to develop, produce and distribute products for the diagnosis and potential treatment of cancer. The products are based on proprietary nuclear matrix protein technology. The group has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. The group's products include NMP221 test kit for bladder cancer, NMP179 for cervical cancer and nmp66 for breast cancer. The major customers of the group include Institut Fur Klinische and Fisher.
|
|
Name |
Title
|
Email
|
| Stephen Chubb | Chmn., CEO | N/A | | Franz Maier | Pres. - Matritech Gmbh | N/A | | David Corbet | Dir., COO, Pres. | N/A | | Richard Sandberg | Dir., VP - Finance, CFO, Treasurer, Assist. Sec. | N/A | | David Kolasinski | VP - Sales | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 12,195 | (11,935) | | 2005 | 10,415 | (7,865) | | 2004 | 7,483 | (11,123)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
